Amoybrand

Tenofovir Alafenamide Fumarate / TAF 1392275-56-7
Tenofovir Alafenamide Fumarate / TAF 1392275-56-7

Tenofovir Alafenamide Fumarate / TAF 1392275-56-7

DMF, for R&D use
  • Product Detail

Product Information


Product name

Tenofovir Alafenamide Fumarate / TAF

CAS No.

1392275-56-7

Molecular Formula

2(C21H29N6O5P).C4H4O4

Molecular Weight

1069.00

Quality Standard

98% up, Medicine Grade

Appearance

White powder


COA of Tenofovir Alafenamide Fumarate / TAF




Usage


Function of Tenofovir Alafenamide Fumarate / TAF

Tenofovir Alafenamide Fumarate / TAF is a novel nucleotide reverse transcriptase inhibitor for the treatment of chronic hepatitis B virus infection and compensatory liver disease.

Tenofovir alafluamine fumarate is an oral prodrug of tenofovir (TFV), a modified version of the commercially available drug tenofovir disoproxil fumarate (TDF). Compared with TDF, TAF has a smaller clinical dose and is easier to enter the cell. The virus acts more strongly and the adverse reactions are reduced.

API TAF was approved by the COS on November 10, 2016 for the treatment of adult patients with chronic hepatitis B infection. PMDA was approved on December 19, 2016 and approved by EMA in 2017.1.9, becoming the first hepatitis B drug approved for listing in Europe in the past 10 years. Approved for the treatment of HIV infection, all three drugs are based on tenofovir alafenamide fumarate.


leave a message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
categories

Get Daily Update We’ll never share your email address with a third-party.

leave a message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.